Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosomes for Ocular Sjögren's Syndrome
NCT07192666Phase 1Not yet recruiting
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Lipid-based Nanoparticles
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cell exosomes in Sjögren's syndrome, sponsored by Guangdong ProCapZoom Biosciences Co., Ltd. Primary endpoint: Adverse events (AEs) at Day 29. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT07192666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192666.